Clinical Trials on Recurrent Prostate Cancer in New Zealand

Total 8608 results

Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

Prostate Cancer

United States
Rutgers, The State University of New Jersey
Memorial Sloan Kettering Cancer Center; Fox Chase Cancer Center; Rutgers Cancer...

Completed

Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer

Prostate Cancer | Sexuality | Sexual Dysfunction and Infertility

United States
University of Wisconsin, Madison
Madison Vaccines Incorporated

Completed

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Prostate Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline; University of Washington

Completed

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

Prostate Cancer | Castration-resistant, Metastatic

United States
Arvinas Androgen Receptor, Inc.

Active, not recruiting

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Metastatic

United States
NYU Langone Health
Novartis

Completed

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Prostatic Neoplasms | Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
University of California, Los Angeles; Ferring Pharmaceuticals; Wayne State University and other collaborators

Completed

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Prostate Cancer

United States
Progenics Pharmaceuticals, Inc.

Completed

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Prostate Cancer

United States
American College of Radiology Imaging Network
National Cancer Institute (NCI)

Completed

Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer

Prostate Cancer

United States
Vaccitech (UK) Limited

Recruiting

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Prostate Cancer

United States
Tavanta Therapeutics

Completed

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Metastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
Endocyte

Completed

Phase 1 of EC1169 In Patients With Recurrent MCRPC

Prostate Cancer

United States
Duke University
Astellas Pharma Inc; Medivation, Inc.

Completed

Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (STREAM)

Prostate Cancer

United States
Duke University
Sanofi; Pfizer

Terminated

Multimodality Phase II Study in Prostate Cancer

Prostate Cancer

United States
GenomeDx Biosciences Corp
Columbia University

Completed

Multi-site Decision Impact Study for Decipher (ASSESS-D)

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

Prostate Cancer

United States
VA Office of Research and Development
Sanofi

Completed

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma (CAP)

Prostate Cancer

United States, Puerto Rico
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
Karolinska Institutet
University Health Network, Toronto; University of Chicago; University of Illinois... and other collaborators

Completed

Stockholm3 Validation Study in a Multi-Ethnic Cohort (SEPTA)

Prostate Cancer (Diagnosis)

United States, Canada
Aptevo Therapeutics

Completed

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, Australia
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage III Colon Cancer | Stage III Rectal Cancer

United States
Royal North Shore Hospital

Completed

Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose

Cancer of the Prostate

Australia
Amgen

Completed

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Cancer | Breast Cancer | Breast Neoplasms | Metastatic Cancer | Breast Tumors | Solid Tumors | Oncology | Tumors | Metastases | Locally Recurrent and Metastatic Breast Cancer

United States, Belgium, France
Costantine Albany
Hoosier Cancer Research Network; Achieve Life Sciences

Terminated

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Prostate Cancer | PSA | Metastatic Castrate-Resistant Prostate Cancer

United States, Canada
Kiniksa Pharmaceuticals (UK), Ltd.

Completed

A Pilot Study of KPL-914 in Recurrent Pericarditis

Recurrent Pericarditis

United States
Nymox Corporation

Completed

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Researching the Effect of Exercise on Cancer

Breast Cancer | Colorectal Cancer | Prostate Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage III Breast Cancer | Stage III Colorectal Cancer | Stage I Colorectal Cancer | Stage II Colorectal Cancer

United States
Rutgers, The State University of New Jersey
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

Prostate Cancer

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)

Prostate Cancer | Cancer of the Prostate | Nonmetastatic Castration-Resistant Prostate Cancer

Hong Kong, Canada, China, Germany, Spain, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Australia, Denmark, France, United States, Singapore, Poland, Malaysia, Turkey, Belgium, Argentina, Thailand, Slovakia, Brazil, Finland, Ita... and more
Millennium Pharmaceuticals, Inc.

Completed

A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer

Prostate Cancer

United States
Innocrin Pharmaceutical
Prostate Cancer Foundation; Prostate Cancer Clinical Trials Consortium

Completed

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Prostate Cancer

United States
National Cancer Institute (NCI)
Wayne State University; Columbia University; University of Pittsburgh; University... and other collaborators

Completed

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

Prostate Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Prostate Cancer

United States
M.D. Anderson Cancer Center

Unknown

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy

Prostate Cancer

United States
Weill Medical College of Cornell University

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer

United States
POINT Biopharma, a wholly owned subsidiary of Eli...

Active, not recruiting

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, Sweden, France, United Kingdom
Amgen

Active, not recruiting

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (DeLLpro-300)

Neuroendocrine Prostate Cancer

Belgium, United States, Austria, Spain, Australia, Netherlands, France, United Kingdom, Japan
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
Memorial Sloan Kettering Cancer Center
Aureon Biosciences, Inc.; NYU MEDICAL CENTER

Completed

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

Prostate Cancer

United States
Herbert Irving Comprehensive Cancer Center

Unknown

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Prostate Cancer

United States

Clinical Trials on Recurrent Prostate Cancer in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations